NASDAQ:FATE Fate Therapeutics (FATE) Stock Price, News & Analysis $1.35 +0.02 (+1.50%) As of 04/24/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Fate Therapeutics Stock (NASDAQ:FATE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Fate Therapeutics alerts:Sign Up Key Stats Today's Range$1.29▼$1.3950-Day Range$0.68▼$1.7152-Week Range$0.66▼$5.92Volume1.55 million shsAverage Volume2.32 million shsMarket Capitalization$154.72 millionP/E RatioN/ADividend YieldN/APrice Target$5.43Consensus RatingHold Company OverviewFate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.Read More… Fate Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks73rd Percentile Overall ScoreFATE MarketRank™: Fate Therapeutics scored higher than 73% of companies evaluated by MarketBeat, and ranked 255th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingFate Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.22, and is based on 2 buy ratings, 7 hold ratings, and no sell ratings.Amount of Analyst CoverageFate Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Fate Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Fate Therapeutics are expected to decrease in the coming year, from ($1.63) to ($1.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fate Therapeutics is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fate Therapeutics is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFate Therapeutics has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Fate Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.13% of the float of Fate Therapeutics has been sold short.Short Interest Ratio / Days to CoverFate Therapeutics has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Fate Therapeutics has recently increased by 12.35%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldFate Therapeutics does not currently pay a dividend.Dividend GrowthFate Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.70 Percentage of Shares Shorted15.13% of the float of Fate Therapeutics has been sold short.Short Interest Ratio / Days to CoverFate Therapeutics has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Fate Therapeutics has recently increased by 12.35%, indicating that investor sentiment is decreasing significantly. News and Social Media3.0 / 5News Sentiment1.38 News SentimentFate Therapeutics has a news sentiment score of 1.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Fate Therapeutics this week, compared to 3 articles on an average week.Search Interest3 people have searched for FATE on MarketBeat in the last 30 days. MarketBeat FollowsOnly 2 people have added Fate Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Fate Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.00% of the stock of Fate Therapeutics is held by insiders.Percentage Held by Institutions97.54% of the stock of Fate Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Fate Therapeutics' insider trading history. Receive FATE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address FATE Stock News HeadlinesFate Therapeutics receives RMAT designation from FDA for FT819April 14, 2025 | markets.businessinsider.comFate Therapeutics Stock Draws Investor Attention After FDA Grants Special Designation To Its CAR T-Cell Therapy: Retail Stays OptimisticApril 14, 2025 | msn.comCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess. The news is screaming fear. But while most traders watch their portfolios tank…April 25, 2025 | Crypto Swap Profits (Ad)Fate Therapeutics gets RMAT status from FDA for Lupus treatmentApril 14, 2025 | msn.comFate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)April 14, 2025 | globenewswire.comFate Therapeutics (FATE) Down 34.6% Since Last Earnings Report: Can It Rebound?April 4, 2025 | msn.comFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)April 2, 2025 | globenewswire.comFate Therapeutics’ SWOT analysis: promising pipeline drives stock outlookMarch 14, 2025 | investing.comSee More Headlines FATE Stock Analysis - Frequently Asked Questions How have FATE shares performed this year? Fate Therapeutics' stock was trading at $1.65 at the beginning of the year. Since then, FATE stock has decreased by 18.2% and is now trading at $1.35. View the best growth stocks for 2025 here. How were Fate Therapeutics' earnings last quarter? Fate Therapeutics, Inc. (NASDAQ:FATE) released its quarterly earnings results on Wednesday, March, 5th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.13. The biopharmaceutical company had revenue of $1.86 million for the quarter, compared to analyst estimates of $1.57 million. Fate Therapeutics had a negative trailing twelve-month return on equity of 45.88% and a negative net margin of 1,325.43%. Who are Fate Therapeutics' major shareholders? Fate Therapeutics' top institutional shareholders include Assenagon Asset Management S.A. (0.26%) and Exchange Traded Concepts LLC (0.12%). Insiders that own company stock include Redmile Group, Llc, J Scott Wolchko, Bahram Valamehr, John Mendlein, Jerome Charles Bressi, Cindy Tahl, Yu-Waye Chu, Mark Plavsic, Edward J Dulac III, Brian T Powl and Yuan Xu. View institutional ownership trends. How do I buy shares of Fate Therapeutics? Shares of FATE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Fate Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fate Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Cara Therapeutics (CARA), Meta Platforms (META), Alibaba Group (BABA) and Netflix (NFLX). Company Calendar Last Earnings3/05/2025Today4/24/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:FATE CIK1434316 Webwww.fatetherapeutics.com Phone(858) 875-1800FaxN/AEmployees550Year FoundedN/APrice Target and Rating Average Stock Price Target$5.43 High Stock Price Target$9.00 Low Stock Price Target$3.00 Potential Upside/Downside+302.1%Consensus RatingHold Rating Score (0-4)2.22 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-160,930,000.00 Net Margins-1,325.43% Pretax Margin-1,325.43% Return on Equity-45.88% Return on Assets-33.95% Debt Debt-to-Equity RatioN/A Current Ratio8.29 Quick Ratio8.29 Sales & Book Value Annual Sales$13.63 million Price / Sales11.35 Cash FlowN/A Price / Cash FlowN/A Book Value$3.74 per share Price / Book0.36Miscellaneous Outstanding Shares114,604,000Free Float108,199,000Market Cap$154.72 million OptionableOptionable Beta2.41 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:FATE) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.